Compare Abeona Therapeutics Inc (ABEO) vs Badger Meter Inc (BMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Badger Meter Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Badger Meter Inc trades at $146.42 (market cap $4.37B). The key difference: Badger Meter Inc is far larger — about 11.7× Abeona Therapeutics Inc's market cap, and Badger Meter Inc pays a 1.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BMI | |
|---|---|---|
Market Cap | $373.32M | $4.37B |
Sector | Health | Technology |
52-Week High | $7.23 | $245.81 |
52-Week Low | $4.17 | $113.41 |
Enterprise Value | $228.22M | $4.17B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Badger Meter (BMI) trades at $149.79, up 2.69% with a bullish technical signal from moving averages. The company maintains strong profitability with 14.56% net income margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create headwinds. Valuation metrics show a P/E of 33.89 and P/S of 4.93, above industry averages.
While BMI demonstrates solid fundamentals and technical strength, the stock faces significant legal risks from multiple class action lawsuits alleging securities fraud. Analyst consensus is mixed with 28% buy ratings but a $144.80 price target below current levels. The combination of legal overhang and premium valuation creates a cautious near-term outlook despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
